AI Article Synopsis
- ERCC1 is important for the nucleotide excision repair (NER) pathway, which helps fix DNA damage.
- There has been a lot of research on ERCC1's role in predicting outcomes for cancer patients, particularly those with non-small-cell lung cancer.
- Before ERCC1 can be used as a reliable biomarker for classifying patients or directing platinum-based treatments, several unanswered questions need to be addressed.
Article Abstract
Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200610 | PMC |
| http://dx.doi.org/10.3978/j.issn.2305-5839.2013.12.01 | DOI Listing |
Publication Analysis
Top Keywords
lung cancer
8
excision repair
8
ercc1 personalized
4
personalized medicine
4
medicine lung
4
cancer excision
4
repair cross-complementing
4
cross-complementing group
4
group ercc1
4
ercc1 key
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!